News | September 26, 2012

New IMV Survey Shows Aging of Installed MR Scanners in the U.S.

Average age of installed MRI scanners in U.S. has increased, according to new market research report by IMV

IMV Medical Information Division MRI Systems Clinical Trial

September 26, 2012 — The average age of installed magnetic resonance imaging (MRI) scanners in the United States has increased from eight years in 2007 to 10.9 years in 2011, according to a new market research report by IMV Medical Information Division.

“The last spike of new MR installations extended from 2002 to 2004,” observed Lorna Young, senior director, market research at IMV. “The research finds that the MRI market is ready for replacement of the older units that are at the end of their useful lives. Providers are also planning to take advantage of the wider bore sizes that are now available."

Survey results indicate that two out of every three new MR installations will be wide-bore. Young noted that 1.5T units are still the mainstay of the modality, representing 70 percent of all recently installed MR scanners and 70 percent of all systems currently in place.

While overall procedures performed in the United States rose an estimated 6 percent to 32 million procedures from 2010 to 2011, utilization at the site level increased 4 percent and the average number of MR procedures performed per scanner fell 4 percent. Respondents reported that reductions in reimbursements, from both Medicare and third-party payors, caused their MR revenues to decline despite the slight increase in utilization.

Lower and upper extremity procedures grew 15 percent from 2010 to 2011, making these applications the biggest contributor to MR procedure growth, the research found. Other areas of MR procedure growth were orthopedic and neurological procedures.   

The risk of nephrogenic system fibrosis (NSF) remains a concern for providers considering the use of gadolinium-based contrast agents (GBCA). More than 75 percent of the survey respondents stated that NSF prevention is a priority patient-management issue for their departments.

The report describes trends in MR patient exams by procedure type, MR installed base by manufacturer and year of installation, planned purchases and market scenarios for unit sales through 2016, contrast media expenditures by supplier, site operations characteristics, and department managers' opinions about the factors affecting the future outlook for MR at their facility. Other report highlights include:

  • 63 percent of all MR studies were performed in hospitals or in hospital-owned imaging centers.
  • 22 percent of all MR users plan on purchasing a new system in the next three years.
  • 6 percent of all MR sites use a mobile service.
  • 37 percent of all MR procedures used contrast in 2011, declining from 42 percent in 2010.
  • Spine, brain, and lower and upper extremities comprised the four largest categories of MR procedures.


For more information: www.MReport.imvinfo.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now